Diazepam — research review 1

...So, let's talk about diazepam. It’s a GABA-A modulator, often used for muscle spasms, and can be really helpful for acute pain. But the long-term picture, especially for older adults, is complex when we consider biological aging and all-cause mortality.

Exactly. While pain relief is crucial – we know unrelieved pain itself can accelerate biological aging, like in painful diabetic neuropathy, where we see accelerated epigenetic aging and telomere shortening compared to painless neuropathy. That’s from a GeroScience 2025 study.

Right, so the goal is to manage pain effectively. However, the evidence also suggests potential downsides with certain treatments. For instance, diazepam has been associated with mild cognitive impairment. A study in Int Psychogeriatr 2023 found that benzodiazepine use is linked to developing mild cognitive impairment in otherwise cognitively normal older adults.

That’s a significant concern, especially when we’re looking at overall healthy aging. And while this data points to associations, it's not definitively proving causation for all-cause mortality or direct acceleration of biological aging in every scenario. The long-term effects on epigenetic clocks, for example, aren’t fully established for diazepam specifically.

So, it's about weighing the known benefits for supervised, appropriate use against these potential long-term risks, and recognizing what we still need more research on. We have evidence of cognitive impact and accelerated aging from untreated pain, but the direct, causal link between diazepam and accelerated biological aging or increased all-cause mortality across populations is still something researchers are actively investigating.